EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment

Masato Hamasaki, Naoki Sakane iD, Kazuhiko Kotani iD

Nutrients · 2024

DOI: 10.3390/nu16213686 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2024. Verfasst von Masato Hamasaki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan. Hauptthemen laut MEDLINE: Proprotein Convertase 9, Non-alcoholic Fatty Liver Disease, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hyperlipoproteinemia Type II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Fatty acids are involved in some hepatic disorders. The proprotein convertase subtilisin kexin 9 (PCSK9) inhibits the uptake of low-density lipoproteins (LDLs), which contain lipids, into the liver and may thus be associated with nonalcoholic fatty liver disease (NAFLD), a cardiovascular disorder (CVD) risk. Statins reduce blood LDL–cholesterol (LDL-C) levels and CVD risk and can attenuate the development of NAFLD while increasing blood PCSK9 levels.

Methods

We investigated the correlation between PCSK9 and liver conditions in patients with familial hypercholesterolemia (FH), a CVD risk population with elevated blood LDL-C levels, under statin treatment. Blood tests for lipids, PCSK9, and liver function (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) were performed in patients with FH taking statins (n = 25, mean age = 57 years, 12% of males). The ALT:AST ratio was used as a marker of NAFLD risk.

Results

The mean LDL-C level was 3.38 mmol/L, and the median PCSK9 level was 312 ng/mL. The median ALT:AST ratio was 0.88. A significant negative correlation was observed between the PCSK9 and ALT:AST ratio (β = −0.67, p < 0.05).

Conclusions

Their negative correlation might give a hypothetical insight into the effect of statin treatment on the development of NAFLD, in relation to PCSK9 behavior, in patients with FH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proprotein Convertase 9Non-alcoholic Fatty Liver DiseaseHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipoproteinemia Type IICholesterol, LDLHumansMaleFemaleMiddle AgedAlanine TransaminaseAgedAspartate AminotransferasesRisk FactorsBiomarkersAdultLiver

Stichwörter der Autor:innen

HMG-CoA reductase inhibitorfatty acidsfatty liver diseaselipid-lowering therapy

Substanzen

Proprotein Convertase 9Hydroxymethylglutaryl-CoA Reductase InhibitorsPCSK9 protein, humanCholesterol, LDLAlanine TransaminaseAspartate AminotransferasesBiomarkers

Autor:innen und Institutionen

  • Division of Community and Family Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke 329-0498, Japan.
  • Division of Preventive Medicine, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, 1-1 Fushimi-Ku, Kyoto 612-8555, Japan.

ORCID-Profile: Naoki Sakane, Kazuhiko Kotani

Zitieren

APA

Hamasaki, M., Sakane, N., & Kotani, K. (2024). Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. Nutrients. https://doi.org/10.3390/nu16213686

Vancouver

Hamasaki M, Sakane N, Kotani K. Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. Nutrients. 2024. doi:10.3390/nu16213686

BibTeX
@article{Hamasaki2024,
  author = {Hamasaki, Masato and Sakane, Naoki and Kotani, Kazuhiko},
  title = {Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16213686}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche